Beta-Blockers as Potential Adjuvants in Melanoma Treatment

Area of Science:

• Oncology
• Pharmacology
• Dermatology

Background:

• Advanced melanoma presents significant therapeutic challenges due to limited treatment efficacy.
• Rising melanoma incidence necessitates novel and more effective treatment strategies.
• Beta-blockers, primarily used for cardiac conditions, are being investigated for repurposing in cancer therapy.

Purpose of the Study:

• To evaluate the efficacy of beta-blockers as a potential repurposed treatment for melanoma.
• To assess the effects of specific beta-blockers (carvedilol, propranolol, atenolol, metoprolol) and chemotherapy drugs (cisplatin, 5-fluorouracil) on melanoma cell viability.
• To investigate synergistic interactions between beta-blockers and chemotherapy agents in melanoma treatment.

Main Methods:

• In vitro study using the A375 melanoma cell line.
• Assessment of cell viability over 72 hours following exposure to various drug concentrations.
• Determination of half-maximal inhibitory concentrations (IC50s) for individual and combined drug exposures.

Main Results:

• Cisplatin and 5-fluorouracil demonstrated higher toxicity than carvedilol and propranolol.
• Atenolol and metoprolol (beta-1 selective blockers) showed no significant impact on melanoma cell viability at tested concentrations.
• Carvedilol and metoprolol exhibited synergistic effects with cisplatin at specific concentrations, indicating enhanced anti-cancer activity.

Conclusions:

• Beta-blockers demonstrate concentration-dependent effects on melanoma cells.
• Carvedilol and metoprolol show promise for melanoma treatment, particularly in combination therapies with chemotherapy.
• Repurposing beta-blockers represents a potential new therapeutic avenue for advanced melanoma.